Background. The impact of loop electrosurgical excision procedure (LEEP) treatment for cervical precancerous lesions on subsequent acquisition of new human papillomavirus (HPV) infections is not well described.
moves the epithelium and a small amount of underlying stroma from the entire cervical transformation zone, tissue that is uniquely susceptible to oncogenic transformation by human papillomavirus (HPV). Among women with Ͼ1 HPV-related cervical lesion, it is likely that LEEP removes both colposcopically apparent and inapparent lesions. Cervical infections by cancerassociated or carcinogenic HPV genotypes cause virtually all cases of cervical cancer [1, 2] and the majority of CIN2/3 lesions [3] ; numerous studies have shown that successful treatment of CIN2/3 by LEEP is accompanied by disappearance of the causal HPV genotype and that treatment failure is associated with persistence of the causal HPV genotype during post-LEEP follow-up [4 -9] . On the basis of these data, follow-up testing for carcinogenic HPV is now accepted as an option for post-LEEP monitoring for recurrent disease [10, 11] .
However, few studies have examined the impact of LEEP on the acquisition of new HPV infections. It is unclear whether temporarily removing the susceptible tissue through excision, with subsequent epithelial healing, might also reduce acquisition of HPV infection. If so, LEEP could potentially decrease the risk of subsequent cervical cancer from HPV genotypes not present when the first CIN2/3 lesion is treated. To evaluate the effects of LEEP on the natural history of HPV infection, we conducted a retrospective analysis to compare rates of acquisition for HPV infection between women treated by LEEP and a comparison group of HPV-positive, colposcopically evaluated women who did not undergo LEEP during the enrollment period of the ASCUS (atypical squamous cells of undetermined significance)-LSIL (low-grade squamous intraepithelial lesion) Triage Study (ALTS) [12] [13] [14] [15] [16] . We examined the impact of LEEP on the subsequent acquisition of new HPV infections, first for individual HPV genotypes and then for groups of HPV genotypes related by cancer risk or genetic composition.
MATERIALS AND METHODS
Study design and population. The ALTS, conducted during 1997-2001, was a multisite, randomized trial comparing 3 management strategies for women with ASCUS (3488 women) or LSIL (1572 women) conventional cytology [12] [13] [14] [15] [16] . The National Cancer Institute and local institutional review boards approved the study, and all participants provided written informed consent.
At enrollment and follow-up visits, all women underwent pelvic examinations that involved collection of 2 cervical specimens. The first specimen was stored in PreservCyt transport medium for cytological analysis by ThinPrep (Hologic [formerly Cytyc]), and the second was stored in STM transport medium (Qiagen [formerly Digene]). Women in all 3 arms of the study underwent cytological reevaluation every 6 months for 2 years and were sent for colposcopy if cytological testing revealed a high-grade squamous intraepithelial lesion. An exit examination with colposcopy was scheduled for all women. Details on randomization, examination procedures, patient management, and laboratory and pathological analyses have been reported elsewhere [12] .
HPV genotyping. Cervical specimens were tested for at least 27 HPV genotypes (most specimens underwent testing for 38 HPV genotypes), using an L1-based polymerase chain reaction (PCR) assay that employs a primer set designated PGMY09/11, as described elsewhere [17] [18] [19] . All specimens were analyzed for HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68, which were considered carcinogenic [20, 21] .
Pathological findings and treatment. Clinical management was based primarily on the clinical center pathologists' cytological interpretations and histological diagnoses, as described elsewhere [12] [13] [14] [15] [16] . Referral smears, ThinPrep slides, and slides for histological analysis were also sent to the Pathology Quality Control Group (QC Pathology), based at the Johns Hopkins Hospital, for review (including computer-assisted review) and secondary diagnoses, as described elsewhere [12] [13] [14] [15] [16] . A histological diagnosis of CIN grade 2 (hereafter, "CIN2"), based on the clinical center pathologists' report, or CIN3, based on the QC Pathology review, triggered LEEP treatment. Women with a persistent low-grade lesion at the time of exit from the study were offered LEEP.
Statistical analysis. We restricted this analysis to women with test results only from the laboratory that tested for 38 HPV genotypes (approximately half of the enrollment specimens and all of the follow-up specimens) because of analytical sensitivity differences between this laboratory and the laboratory that tested for 27 HPV genotypes in a subset of enrollment specimens (data not shown). Women who underwent testing for 38 HPV genotypes were more likely to be referred into ALTS because of an ASCUS Pap than were women who underwent testing for 27 HPV genotypes (P Ͻ .001), but there were no significant differences between these groups in the lifetime number of sexual partners (0 -3, 4 -5, 6 -9, or 10 partners) to suggest that one group was more likely than the other to acquire new HPV infections. We compared the acquisition of HPV genotypes among 195 HPV-positive women who underwent LEEP at baseline with the acquisition of HPV genotypes among 1625 HPV-positive women who underwent colposcopy but not LEEP at baseline (i.e., women with a diagnosis of CIN grade of Ͻ2; hereafter, "ϽCIN2"). This strategy allowed us to examine the impact of LEEP over the 2 years of follow-up in the ALTS. Women in either group who underwent LEEP during follow-up were censored and did not contribute observation time after LEEP to either group.
Our analysis considered each woman's possible acquisition of each of 38 HPV genotypes as a unit of analysis, under the assumption that the natural history of HPV genotypes is independent of whether other HPV genotypes are present [22, 23] . We excluded the observation for presence or absence during follow-up of genotypes that were detected at enrollment, because a subsequent positive finding could be considered a failure of LEEP, not a new acquisition of infection.
We also considered the acquisition of the following groups of HPV genotypes: all HPV genotypes, carcinogenic HPV genotypes, and noncarcinogenic HPV genotypes. In addition, we evaluated the acquisition of HPV genotypes according to the following phylogenetic species groups [24, 25] : ␣1/8/10 (HPV-6, 11, -40, -42, and -55), ␣3/4/15 (HPV-57, -61, -62, -71, -72, -81, -83, -84, and -89), ␣5 (HPV-26, -51, -69, and -82), ␣6 (HPV-53, -56, and -66), ␣7 (HPV-18, -39, -45, -59, -68, and -70), ␣9 (HPV-16, -31, -33, -35, -52, -58, and -67), and ␣11 (HPV-64 and -73). HPV-40 (␣8) and HPV-54 (␣13) were the only HPV genotypes from their respective species detected by the assay and so were presented only as individual HPV genotypes.
The prevalence at baseline of individual HPV genotypes was assessed for each study group, with odds ratios calculated, and the Pearson 2 test was used to test for differences in prevalence at baseline. Cumulative incidence rate ratios (IRRs) for treated versus untreated women and 95% confidence intervals (CIs) were calculated for individual HPV genotypes and categories of HPV genotypes, as described above.
An obvious concern in this study design is that women treated by LEEP were more likely to have HPV genotypes at enrollment that are linked to a risk of CIN2. Because we were studying only subsequent new infections, the numbers of women who were eligible to acquire those high-risk infections during follow-up were reduced in the treated group. The IRR for each individual genotype was calculated as the ratio of new infections among eligible women, which adjusted for this issue. However, a weighted stratified analysis was needed for the study of categories, which took into account the numbers of women eligible for new infections with each genotype in that category. The weights are shown in table 1. The best example of the impact of this difference is for HPV-16: 55.9% of women who underwent LEEP for CIN2 were positive for HPV-16, compared with 20.1% of untreated women. This means that only 44.1% of treated women, compared with 79.9% of untreated women, could acquire HPV-16 during follow-up if weights were not used in our analytic approach. Thus, HPV categories that include HPV-16 (i.e., all combined carcinogenic HPV and ␣9 phylogenetic species) would have been directly influenced by these differences in the prevalence of HPV-16 at baseline. Accordingly, strata were defined by a specific LEEP status and specific HPV genotype. The weight for a given stratum was the ratio of the total number of women in the stratum who had the specific LEEP status to the number of women in the stratum who contributed an observation. For example, among the 1625 untreated women, 326 were positive for HPV-16 at enrollment, so only the remaining 1299 women contributed a record to the HPV-16 stratum for untreated women. Therefore, the weight for this stratum, 1.25, was calculated as follows: 1625/1299. Similarly, 109 of 195 treated women were positive for HPV-16 at enrollment, so the number of infections observed during follow-up was multiplied by 2.27, which was calculated as follows: 195/[195 Ϫ 109].
SUDAAN software and subsequent calculations accounted for these weighting factors in estimations of the IRR, defined as the ratio of the complement of the weighted Kaplan-Meier estimate (i.e., the cumulative incidence rate [CIR]) among women treated by LEEP to the complement of the weighted KaplanMeier estimate among women not treated by LEEP. The variance for the log cumulative IRR was obtained by applying the delta method [26] : for each group, the variance contribution was the ratio of the variance estimate calculated in SUDAAN, assuming stratified sampling with replacement, to the square of the cumulative incidence estimate. This delta method result was used in calculating the asymmetric CIs for the cumulative IRRs.
To allow for correlation of multiple infections in the same woman (which, a priori, we expected to be null), an analysis that considers each woman as a cluster was also conducted, using SUDAAN software to calculate the weighted Kaplan-Meier estimates and the variance estimates. The variance for the log cumulative IRR was calculated using the delta method, and the asymmetric CI was calculated. A similar analysis was performed using SUDAAN and the proportional hazards model with cluster data. The results of these alternative approaches were similar to those of the approach that did not treat each woman as a cluster. Because these estimates confirmed our prior assumption that the infections act independently, without autocorrelation within women, the estimates were not presented.
RESULTS
The prevalence at baseline of individual HPV genotypes detected for each study (HPV-positive) group are shown in table 1. There were significant overall differences in the distribution of HPV genotypes (P Ͻ .001). As expected, HPV-16 was detected significantly more frequently among treated women than among untreated women (P Ͻ .001). Conversely, untreated women were more likely than treated women to have an HPV-42 infection at enrollment (P ϭ . The prevalence at baseline of HPV genotypes grouped according to phylogenetic clade or cancer risk detected for each HPVpositive study group is also shown in table 1. HPV genotypes in the ␣9 phylogenetic species and those in the carcinogenic HPV risk group were much more common among patients who underwent LEEP than among untreated patients (P Ͻ .001). Figure 2 shows the cumulative IRR for HPV groups at 6-month and 24-month follow-up visits. There was no differ- Table 1 . Baseline prevalence of individual human papillomavirus (HPV) genotypes and groups of HPV genotypes in HPV-positive women treated by loop electrosurgical excision procedure (LEEP) at enrollment and HPV-positive women who underwent colposcopy but not LEEP at enrollment. In analysis of HPV genotypes grouped according to phylogenetic species and groups of species, the ␣9 species, which is composed predominately of carcinogenic HPV genotypes (with the exception of HPV-67), was the only species that differed significantly between treated and untreated women. Treated women were 56% less likely than untreated women to have ␣9 HPV genotypes detected at the 6-month follow-up visit (IRR, 0.44; 95% CI, 0.23-0.85) and 40% less likely to have these genotypes detected at the 24-month follow-up visit (IRR, 0.60; 95% CI, 0.42-0.85). When HPV-16 was excluded, treated women were 50% less likely than untreated women to have ␣9 HPV genotypes detected at the 6-month follow-up visit (IRR, 0.50; 95% CI, 0.26 -0.97) and 44% less likely to have these genotypes detected at the 24-month follow-up visit (IRR, 0.56; 95% CI, 0.38 -0.81).
We did not observe meaningful differences in the IRRs for ␣9 genotypes between the subgroups of women with different phylogenetic species groups of HPV genotypes prevalent at baseline (table 2). The IRRs for ␣9 genotypes for subgroups with different phylogenetic HPV genotypes at baseline ranged from 0.46 (for women with ␣1/␣8/␣10 genotypes at baseline) to 0.78 (for women with ␣3/␣4/␣15, ␣5, or ␣6 genotypes at baseline)
There was no indication of a difference between study groups in the self-reported number of new sexual partners during each follow-up visit (P ϭ .2 at 6 months, P ϭ .8 at 12 months, P ϭ .2 at 18 months, and P ϭ .3 at 24 months, by the Fisher exact test) or in enrollment age (P Ͼ .999, by the Kruskal-Wallis test) (data not shown). Women who underwent LEEP at enrollment reported more person-years of smoking (P ϭ .006, by the Kruskal-Wallis test) and marginally more person-years of oral contraceptive use (P ϭ .09, by the Kruskal-Wallis test) than the untreated women, but there was no difference between groups in the self-reported use of condoms (P ϭ .8, by the Kruskal-Wallis test). Treated women had on average fewer visits than untreated women (4.86 vs. 4.96 visits; P ϭ .001), but virtually all women had a 6-month visit (2 women in the LEEP group were censored before the 6-month follow-up visit). Most women in each group (93.3% in the treated group and 97.4% in the untreated group) were followed up for 24 months. Restriction of our analysis to only women with 24 months of follow-up did not appreciably change our findings (data not shown).
DISCUSSION
We determined whether the removal of the cervical transformation zone by LEEP for treatment of CIN2/3 affected subsequent acquisition of HPV infection. We found that excision had little impact on acquisition of HPV infection during the subsequent 6-month and 24-month periods, except for the suggestion that carcinogenic HPV genotypes, particularly those of the ␣9 phylogenetic species (which includes the most carcinogenic HPV genotype, HPV-16), were slightly less likely to be acquired by treated women than by untreated women.
One important limitation of the study was that the treated and untreated women were not completely comparable. Our case and control groups consisted of HPV-positive women who underwent colposcopy: women in the treated group had CIN2, and women in the untreated group did not undergo LEEP because they either had a biopsy-based diagnosis of ϽCIN2 or did not undergo biopsy owing to a lack of worrisome lesions. We restricted our analysis to HPV-positive women because HPVnegative women are likely to have a different probability of acquiring new infections, owing to different recent behavioral characteristics and a different HPV exposure history, regardless of treatment. Nonetheless, any differences between the 2 groups in behaviors related to acquiring infection could distort our finding.
The presence of prevalent HPV-16 with no other ␣9 genotypes at baseline versus the absence of ␣9 genotypes at baseline did not influence the cumulative incidence of non-HPV-16 ␣9 genotypes (data not shown). This suggests that the preponderance of HPV-16 in the LEEP group did not cause significant biological immunity that might alter acquisition rates of genetically related HPV genotypes. This finding is consistent with our findings from the ALTS [22] , showing that the natural history of an HPV infection tended to behave independently of coinfection with another HPV genotype.
Nevertheless, we recognize that women with a diagnosis of CIN2/3 are inherently different from those without that diagnosis and may be more likely to engage in higher-risk behaviors, such as smoking [27] [28] [29] , which are linked to having [30] and acquiring [31] HPV infection. Moreover, we note that the prevalence at baseline of ␣9 genotypes was the most significant difference between study groups, which raises the possibility that a confounding effect due to these differences in the prevalence of ␣9 genotypes at baseline can lead to an apparent protective effect due to LEEP. The only group truly comparable to the treated group would be the group of women with CIN2/3 who were not treated; such a comparison subgroup was not available in the ALTS. As a sensitivity analysis, we repeated our analysis of ␣9 genotype acquisition but restricted our control group to 197 HPV-positive women who were untreated at baseline but had CIN2/3 subsequently diagnosed during follow-up. Many of these subsequent diagnoses undoubtedly represent missed prevalent disease because of the limited sensitivity of colposcopy [32] , and this group is therefore more similar to the treated group in terms of risk behaviors for acquisition of HPV infection. The 6-month and 24-month IRRs for ␣9 HPV genotypes were 0.23 (95% CI, 0.12-0.47) and 0.32 (95% CI, 0.22-0.47), respectively, suggesting that the observed reduction in ␣9 HPV genotype acquisition is not an artifact due to the selection of the control group.
However, we did not observe similar effects for the acquisition of ␣11 HPV genotypes, the phylogenetic species most closely related to ␣9, nor for ␣7 HPV genotypes, the other major carcinogenic HPV genotype-populated phylogenetic species, which raises questions about the veracity of this finding. It is difficult to formulate a biological rationale to explain why there would be an effect on one group (␣9) but not others (␣11 or ␣7), although there are clear examples of phylogenetic species-specific differences in the natural history of HPV infection [25, 33, 34] .
We can speculate about the biological causes only if the phenomenon is real. One possibility is that LEEP, by damaging the cervical tissue, causes an acute inflammatory response that reduces the susceptibility to new HPV infections, but there is no evidence to support such a mechanism or to explain why it would be specific to HPV-16 -related genotypes. We did not find significant differences in self-reported behaviors between the 2 groups that would explain our observations. Indeed, smoking, which has been linked to HPV infection [30] , was more common among the women who underwent baseline treatment than among those who did not, which would tend to mute the possible protective effects of LEEP on the acquisition of HPV infection.
In conclusion, our study found a slight reduction in acquisition of new carcinogenic HPV infections, particularly those due to HPV genotype ␣9, after LEEP. Our findings from this study, which, to our knowledge, is the first to address the impact of LEEP on genotype-specific HPV acquisition, raise the possibility that LEEP has a secondary effect of reducing the subsequent risk of cancer. Because of limitations in the study design, however, we cannot draw a definitive conclusion about the protective effect of LEEP on acquisition of HPV infection, and we urge caution against overinterpretation of this preliminary finding. The minor benefit, if true, must be weighed carefully against the costs of treatment-induced iatrogenic morbidity that may lead to adverse obstetric outcomes [35] [36] [37] . Clearly, additional investigations of this question by means of other study designs are needed.
